Standard-Criteria Kidney Transplant Offers Clear Survival Benefit Over Continued Dialysis

Follow Drugslib on

Medically reviewed by Carmen Pope, BPharm. Last updated on June 10, 2025.

By Elana Gotkine HealthDay Reporter

TUESDAY, June 10, 2025 -- Transplantation with standard-criteria kidney offers a clear survival benefit, but this decreases with age and for those with a history of cardiovascular disease (CVD), according to a study presented at the annual congress of the European Renal Association, held from June 4 to 7 in Vienna.

Rachel Hellemans, M.D., Ph.D., from Antwerp University Hospital in Belgium, and colleagues examined the survival benefit of deceased donor kidney transplantation compared with continued dialysis in waitlisted patients with kidney failure. Data were included for 64,013 patients aged ≥20 years from the European Renal Association Registry database who were on dialysis while waitlisted for a first deceased donor kidney-only transplant.

Overall, 40,441 patients received a kidney transplant, either from a standard criteria donor (SCD)/donation after brain death (DBD), SCD/donation after circulatory death (DCD), expanded criteria donor (ECD)/DBD, or ECD/DCD (45.0, 12.1, 35.2, and 7.7 percent, respectively). The researchers found that higher five-year survival was seen in SCD transplant recipients versus dialysis patients. There was a decrease in survival benefits seen with age in ECD kidney transplant recipients, especially in recipients of DCD kidneys and recipients with CVD comorbidity: five-year survival was 57 and 58 percent for a 75-year-old ECD/DCD recipient or a 75-year-old ECD recipient with CVD, respectively, compared with 54 percent among patients continuing dialysis. In the oldest patients, early posttransplant mortality contributed to the reduced benefit.

"We found that transplantation with standard-criteria kidneys still offers a clear survival benefit at virtually every age, but in the oldest, most comorbid recipients receiving lower-quality organs, that edge can all but disappear," Hellemans said in a statement.

Press Release

More Information

Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

Source: HealthDay

Posted : 2025-06-11 06:00

Read more

Disclaimer

Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.

The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.

Popular Keywords